泛亞國際(06128.HK)完成發行50萬美元首批票據
格隆匯2月1日丨泛亞國際(06128.HK)發佈公吿,2021年1月19日,公司作為發行人與Lexinter International Inc.作為認購人就以不超過總承擔1500萬美元但不少於最低承擔500萬美元的最多本金總額髮行及認購可換股票據及認股權證以及按價格1.00美元購買認股權證訂立認購協議。
先決條件一均獲達成及首批票據完成已於2021年2月1日落實。認購人於2021年2月1日獲發本金額為50萬美元的首批票據。自發行首批票據籌集的所得款項淨額將約為283.7萬港元,將用於贖回向第三方發行的尚未償還債務證券及作為集團一般營運資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.